Tags

Type your tag names separated by a space and hit enter

Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients.
Phytother Res 2019; 33(3):791-797PR

Abstract

The aim of this study was to evaluate a nutraceutical combination containing polyphenols extracted from Ascophyllum nodosum and Fucus vesiculosus and chromium picolinate on glyemic status; secondary outcomes were considered the changes on endothelial markers. We randomized 65 dysglycemic patients to placebo or the nutraceutical agent for 6 months. We evaluated fasting plasma glucose (FPG), postprandial plasma glucose (PPG), HbA1c , fasting plasma insulin, homeostatic model assessment (HOMA) index, high sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), and adhesion molecules. At baseline and at 3 and 6 months, all patients underwent an oral glucose tolerance test. We recorded a reduction of HbA1c , FPG, PPG, and HOMA-IR compared with placebo (p < 0.05). After 6 months, 18.2% of patients retuned to a normal glycemic status in the nutraceutical group versus 0 patients in placebo group (p < 0.05); 69.7% were classified as impaired fasting glycemia and 12.1% as impaired glucose tolerance in the nutraceutical group versus 17.2% and 82.8 in placebo group (p < 0.01) for both. A reduction of Hs-CRP and TNF-α was recorded with the nutraceutical. The administration of a nutraceutical combination containing A. nodosum and F. vesiculosus can be helpful in improving insulin sensitivity and glycemic status. Larger randomized studies are required to confirm the positive effects of these agents.

Authors+Show Affiliations

Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy. Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy.Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30714233

Citation

Derosa, Giuseppe, et al. "Ascophyllum Nodosum and Fucus Vesiculosus On Glycemic Status and On Endothelial Damage Markers in Dysglicemic Patients." Phytotherapy Research : PTR, vol. 33, no. 3, 2019, pp. 791-797.
Derosa G, Cicero AFG, D'Angelo A, et al. Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. Phytother Res. 2019;33(3):791-797.
Derosa, G., Cicero, A. F. G., D'Angelo, A., & Maffioli, P. (2019). Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. Phytotherapy Research : PTR, 33(3), pp. 791-797. doi:10.1002/ptr.6272.
Derosa G, et al. Ascophyllum Nodosum and Fucus Vesiculosus On Glycemic Status and On Endothelial Damage Markers in Dysglicemic Patients. Phytother Res. 2019;33(3):791-797. PubMed PMID: 30714233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. AU - Derosa,Giuseppe, AU - Cicero,Arrigo F G, AU - D'Angelo,Angela, AU - Maffioli,Pamela, Y1 - 2019/02/03/ PY - 2018/07/07/received PY - 2018/12/02/revised PY - 2018/12/09/accepted PY - 2019/2/5/pubmed PY - 2019/6/18/medline PY - 2019/2/5/entrez KW - Ascophyllum nodosum KW - Fucus vesiculosus KW - dysglycemia KW - nutraceutical SP - 791 EP - 797 JF - Phytotherapy research : PTR JO - Phytother Res VL - 33 IS - 3 N2 - The aim of this study was to evaluate a nutraceutical combination containing polyphenols extracted from Ascophyllum nodosum and Fucus vesiculosus and chromium picolinate on glyemic status; secondary outcomes were considered the changes on endothelial markers. We randomized 65 dysglycemic patients to placebo or the nutraceutical agent for 6 months. We evaluated fasting plasma glucose (FPG), postprandial plasma glucose (PPG), HbA1c , fasting plasma insulin, homeostatic model assessment (HOMA) index, high sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), and adhesion molecules. At baseline and at 3 and 6 months, all patients underwent an oral glucose tolerance test. We recorded a reduction of HbA1c , FPG, PPG, and HOMA-IR compared with placebo (p < 0.05). After 6 months, 18.2% of patients retuned to a normal glycemic status in the nutraceutical group versus 0 patients in placebo group (p < 0.05); 69.7% were classified as impaired fasting glycemia and 12.1% as impaired glucose tolerance in the nutraceutical group versus 17.2% and 82.8 in placebo group (p < 0.01) for both. A reduction of Hs-CRP and TNF-α was recorded with the nutraceutical. The administration of a nutraceutical combination containing A. nodosum and F. vesiculosus can be helpful in improving insulin sensitivity and glycemic status. Larger randomized studies are required to confirm the positive effects of these agents. SN - 1099-1573 UR - https://www.unboundmedicine.com/medline/citation/30714233/Ascophyllum_nodosum_and_Fucus_vesiculosus_on_glycemic_status_and_on_endothelial_damage_markers_in_dysglicemic_patients_ L2 - https://doi.org/10.1002/ptr.6272 DB - PRIME DP - Unbound Medicine ER -